Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTBH0VX)

• DTT Name: Histone deacetylase (HDAC)
• Synonyms: Human histone deacetylase
• Gene Name: HDAC
• DTT Type: Successful target; [1]
• UniProt ID: NOUNIPROTAC
• TTD ID: T65755
• Function: Responsible for the deacetylation of lysine residues on the n-terminal part of the core histones (H2a, H2b, H3 and H4). Histone deacetylation givesa tag for epigenetic repression and plays an important role in transcriptional regulation.

Molecular Interaction Atlas (MIA) of This DTT

3 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sodium phenylbutyrate	DMXLBCQ	Spinal muscular atrophy	8B61	Approved	[2]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[1]
HBI-8000	DMDWYUN	Non-small-cell lung cancer	2C25.Y	Registered	[3]

26 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Abexinostat	DM91LGU	Follicular lymphoma	2A80	Phase 3	[4]
CMS-024-02	DMC4X7L	Solid tumour/cancer	2A00-2F9Z	Phase 3	[5]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[6]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[7]
Pracinostat	DMTD7AB	Acute myeloid leukaemia	2A60	Phase 3	[8]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[3]
APH-0812	DM756GE	Human immunodeficiency virus-1 infection	1C62	Phase 2	[9]
DAC-060	DMACTBM	Keratosis	ED56	Phase 2	[10]
JNJ-26481585	DMKIE9C	Advanced stage follicular lymphoma	2A80	Phase 2	[11]
MGCD-0103	DM726HX	Non-small-cell lung cancer	2C25.Y	Phase 2	[3]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[12]
Remetinostat	DMJIB89	Basal cell carcinoma	2C32	Phase 2	[3]
Rocilinostat	DMSTH01	Multiple myeloma	2A83	Phase 2	[13]
SHAPE	DMIQB13	Cutaneous T-cell lymphoma	2B01	Phase 2	[14]
CUDC-907	DMHIQDC	Acute myelogenous leukaemia	2A41	Phase 1/2	[3]
EDO-S101	DMI71FN	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[3]
Tinostamustine	DMA4DMQ	Multiple myeloma	2A83	Phase 1/2	[15]
Tractinostat	DM8D2LC	Lymphoma	2A80-2A86	Phase 1/2	[3]
CG-200745	DM3U2VY	Solid tumour/cancer	2A00-2F9Z	Phase 1	[16]
CT-200	DMW16VR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[17]
CXD-101	DMRD2B0	Solid tumour/cancer	2A00-2F9Z	Phase 1	[18]
GSK311739	DM70DYV	Rhinovirus infection	CA07	Phase 1	[19]
GSK3117391	DMQZSXD	Rheumatoid arthritis	FA20	Phase 1	[20]
OBP-801	DMPLV9G	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
OKI 179	DMSJWTE	Solid tumour/cancer	2A00-2F9Z	Phase 1	[21]
VTR-297	DM9W0B6	Hematologic tumour	2B33.Y	Phase 1	[22]

12 Patented Agent(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ampicidin analog 1	DM2V31C	N. A.	N. A.	Patented	[23]
Ampicidin analog 2	DMZH8S9	N. A.	N. A.	Patented	[23]
Aniline derivative 1	DMDSUGF	N. A.	N. A.	Patented	[24]
Indole-based analog 11	DMVRX7S	N. A.	N. A.	Patented	[24]
Oxazolyl methylthiothiazole derivative 1	DMZM6FW	N. A.	N. A.	Patented	[24]
PMID27376512-Compound-PG-11047	DM5K4YF	N. A.	N. A.	Patented	[25]
PMID27376512-Compound-PG-11048	DM3U7RN	N. A.	N. A.	Patented	[25]
PMID28092474-Compound-32	DMC4TQL	N. A.	N. A.	Patented	[26]
PMID28092474-Compound-33	DMRE6GP	N. A.	N. A.	Patented	[26]
PMID28092474-Compound-34	DM6JRCW	N. A.	N. A.	Patented	[26]
PMID29671355-Compound-53	DMCRWV3	N. A.	N. A.	Patented	[27]
PMID29671355-Compound-69	DMU61XP	N. A.	N. A.	Patented	[27]

1 Preclinical Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CS-00028	DMB4FWX	Solid tumour/cancer	2A00-2F9Z	Preclinical	[28]

1 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MKC-1313	DMAITRL	Solid tumour/cancer	2A00-2F9Z	Terminated	[29]

93 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	DM5LSY9	Discovery agent	N.A.	Investigative	[30]
2,2-bis(3-fluorophenyl)-N-hydroxyacetamide	DMTODR2	Discovery agent	N.A.	Investigative	[31]
2,2-bis(4-chlorophenyl)-N-hydroxyacetamide	DM2RKD6	Discovery agent	N.A.	Investigative	[31]
2,2-bis(4-fluorophenyl)-N-hydroxyacetamide	DM5PWQM	Discovery agent	N.A.	Investigative	[31]
2-(methylsulfonylthio)ethyl 2-propylpentanoate	DMM52D3	Discovery agent	N.A.	Investigative	[32]
4-Benzoylamino-N-hydroxy-benzamide	DMYBPFS	Discovery agent	N.A.	Investigative	[33]
4-Butyrylamino-N-hydroxy-benzamide	DMRY6B4	Discovery agent	N.A.	Investigative	[34]
4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	DM5AVG3	Discovery agent	N.A.	Investigative	[35]
4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	DM0M8G5	Discovery agent	N.A.	Investigative	[36]
4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	DMULOHZ	Discovery agent	N.A.	Investigative	[35]
4-Phenylbutyrohydroxamic acid	DMCZKN7	Discovery agent	N.A.	Investigative	[37]
5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	DM6CRVS	Discovery agent	N.A.	Investigative	[38]
5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione	DM7KQXL	Discovery agent	N.A.	Investigative	[32]
5-Mercapto-pentanoic acid phenylamide	DMET3OJ	Discovery agent	N.A.	Investigative	[36]
6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	DM9LKXD	Discovery agent	N.A.	Investigative	[36]
6-benzenesulfinylhexanoic acid hydroxamide	DM2I95Z	Discovery agent	N.A.	Investigative	[39]
6-benzenesulfonylhexanoic acid hydroxamide	DMY9IK8	Discovery agent	N.A.	Investigative	[39]
6-Mercapto-hexanoic acid phenylamide	DMD2FW9	Discovery agent	N.A.	Investigative	[36]
6-Phenoxy-hexane-1-thiol	DMVYIN2	Discovery agent	N.A.	Investigative	[36]
6-phenylsulfanylhexanoic acid hydroxamide	DM3OLM6	Discovery agent	N.A.	Investigative	[39]
7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	DMLCGSY	Discovery agent	N.A.	Investigative	[30]
7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one	DM28GZ7	Discovery agent	N.A.	Investigative	[40]
7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	DMY027P	Discovery agent	N.A.	Investigative	[30]
7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	DM4VQN8	Discovery agent	N.A.	Investigative	[30]
7-Mercapto-heptanoic acid benzothiazol-2-ylamide	DMPYTHV	Discovery agent	N.A.	Investigative	[36]
7-Mercapto-heptanoic acid biphenyl-3-ylamide	DMEQKPO	Discovery agent	N.A.	Investigative	[36]
7-Mercapto-heptanoic acid biphenyl-4-ylamide	DMJMOUK	Discovery agent	N.A.	Investigative	[36]
7-Mercapto-heptanoic acid phenylamide	DM4912P	Discovery agent	N.A.	Investigative	[36]
7-Mercapto-heptanoic acid pyridin-3-ylamide	DMQ9PLA	Discovery agent	N.A.	Investigative	[36]
7-Mercapto-heptanoic acid quinolin-3-ylamide	DMTAGJ1	Discovery agent	N.A.	Investigative	[36]
8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one	DM23XGW	Discovery agent	N.A.	Investigative	[30]
8-Mercapto-octanoic acid phenylamide	DMD3FWU	Discovery agent	N.A.	Investigative	[36]
8-Oxo-8-phenyl-octanoic acid	DMXDQ25	Discovery agent	N.A.	Investigative	[35]
8-Oxo-8-phenyl-octanoic acid hydroxyamide	DMWM1UL	Discovery agent	N.A.	Investigative	[40]
9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide	DMVBCID	Discovery agent	N.A.	Investigative	[40]
9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one	DMIY3D6	Discovery agent	N.A.	Investigative	[40]
Apicidin	DM83WVF	Solid tumour/cancer	2A00-2F9Z	Investigative	[41]
Azelaic bishydroxamic acid	DMKSQY1	Discovery agent	N.A.	Investigative	[42]
CG-1521	DMN3YEQ	Solid tumour/cancer	2A00-2F9Z	Investigative	[42]
CHAP1	DMBZ0QY	Solid tumour/cancer	2A00-2F9Z	Investigative	[41]
CHAP31	DMOXRID	Solid tumour/cancer	2A00-2F9Z	Investigative	[41]
Cyclostellettamine derivative	DMFTDPQ	Discovery agent	N.A.	Investigative	[43]
N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide	DM5R3ZG	Discovery agent	N.A.	Investigative	[44]
N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide	DMXA9MR	Discovery agent	N.A.	Investigative	[44]
N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide	DMOL79W	Discovery agent	N.A.	Investigative	[44]
N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide	DMTBAPH	Discovery agent	N.A.	Investigative	[44]
N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	DMFYG79	Discovery agent	N.A.	Investigative	[45]
N-(2-aminophenyl)-4-methoxybenzamide	DMTKWUM	Discovery agent	N.A.	Investigative	[46]
N-(2-aminophenyl)nicotinamide	DMRDQ1B	Discovery agent	N.A.	Investigative	[45]
N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	DMDM50P	Discovery agent	N.A.	Investigative	[44]
N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	DM0GOPV	Discovery agent	N.A.	Investigative	[47]
N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	DMJLFOQ	Discovery agent	N.A.	Investigative	[47]
N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide	DMEP2VM	Discovery agent	N.A.	Investigative	[44]
N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide	DM1L3FM	Discovery agent	N.A.	Investigative	[44]
N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	DMC5G6Y	Discovery agent	N.A.	Investigative	[44]
N-(4-aminobiphenyl-3-yl)nicotinamide	DMXVZIY	Discovery agent	N.A.	Investigative	[45]
N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	DMKN8U6	Discovery agent	N.A.	Investigative	[44]
N-(5-Hydroxycarbamoyl-pentyl)-4-methoxy-benzamide	DMUHKYW	Discovery agent	N.A.	Investigative	[48]
N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	DMSUW7M	Discovery agent	N.A.	Investigative	[35]
N-(5-Hydroxycarbamoyl-pentyl)-benzamide	DMZSGPB	Discovery agent	N.A.	Investigative	[48]
N-(6-Hydroxycarbamoyl-hexyl)-benzamide	DMIZVMT	Discovery agent	N.A.	Investigative	[35]
N-(6-Mercapto-hexyl)-benzamide	DM01Y37	Discovery agent	N.A.	Investigative	[36]
N-hydroxy-2,2-diphenylacetamide	DMX3KRQ	Discovery agent	N.A.	Investigative	[31]
N-hydroxy-2,2-diphenylpropanamide	DM7I2TD	Discovery agent	N.A.	Investigative	[31]
N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	DMCN91A	Discovery agent	N.A.	Investigative	[33]
N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	DMVK2Y3	Discovery agent	N.A.	Investigative	[33]
N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	DMHEQ41	Discovery agent	N.A.	Investigative	[33]
N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	DMUOCQB	Discovery agent	N.A.	Investigative	[33]
N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	DMVEOBY	Discovery agent	N.A.	Investigative	[33]
N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	DMISRMT	Discovery agent	N.A.	Investigative	[33]
N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	DMGTNQY	Discovery agent	N.A.	Investigative	[34]
N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	DMDUOH4	Discovery agent	N.A.	Investigative	[34]
N-Hydroxy-4-phenylacetylamino-benzamide	DMCRU17	Discovery agent	N.A.	Investigative	[33]
N-hydroxy-9,10-dihydroanthracene-9-carboxamide	DMID3BF	Discovery agent	N.A.	Investigative	[31]
N-hydroxy-9H-xanthene-9-carboxamide	DM0DRHP	Discovery agent	N.A.	Investigative	[31]
N-Hydroxy-N'-(2-methylphenyl)octanediamide	DM865Y2	Discovery agent	N.A.	Investigative	[44]
N-Hydroxy-N'-(3-methylphenyl)octanediamide	DMYRC2M	Discovery agent	N.A.	Investigative	[44]
N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	DMELB07	Discovery agent	N.A.	Investigative	[44]
N-Hydroxy-N'-(4-methylphenyl)octanediamide	DM3DPZ8	Discovery agent	N.A.	Investigative	[44]
N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	DMZA8NC	Discovery agent	N.A.	Investigative	[49]
Octanedioic acid bis-hydroxyamide	DMJNQ9K	Discovery agent	N.A.	Investigative	[37]
Octanedioic acid hydroxyamide pyridin-2-ylamide	DMHNWS1	Discovery agent	N.A.	Investigative	[35]
Octanedioic acid hydroxyamide pyridin-4-ylamide	DM945RK	Discovery agent	N.A.	Investigative	[35]
PSAMMAPLIN A	DM6T0IQ	Discovery agent	N.A.	Investigative	[40]
ST-2986	DMNERM6	Discovery agent	N.A.	Investigative	[50]
ST-2987	DMWXTM8	Solid tumour/cancer	2A00-2F9Z	Investigative	[50]
ST-3050	DM19K2D	Discovery agent	N.A.	Investigative	[50]
ST-5732	DM9FYPM	Discovery agent	N.A.	Investigative	[51]
Suberic bishydroxamic acid	DM235XH	Discovery agent	N.A.	Investigative	[42]
Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	DMBOKSF	Discovery agent	N.A.	Investigative	[36]
Trapoxin	DMXZAH6	Discovery agent	N.A.	Investigative	[52]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[53]
Trifluoromethylketone	DMEPFAB	Discovery agent	N.A.	Investigative	[42]

References

• [1] Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086.
• [2] Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31.
• [5] US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365).
• [9] Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62.
• [10] Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Correction in: volume 4 on page 1369.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7503).
• [12] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [13] National Cancer Institute Drug Dictionary (drug id 698408).
• [14] Clinical pipeline report, company report or official report of Tetralogic pharmaceuticals.
• [15] The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma. J Hematol Oncol. 2018 Feb 27;11(1):32.
• [16] Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells. PLoS One. 2015 Mar 17;10(3):e0119379.
• [17] Clinical pipeline report, company report or official report of Celleron.
• [18] Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. Clin Microbiol Infect. 2010 Sep;16(9):1482-7.
• [19] Clinical pipeline report, company report or official report of Phrma.org Leading Chronic Diseases Affecting Seniors 2014.
• [20] The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009 January; 10(1): 32-42.
• [21] Clinical pipeline report, company report or official report of OnKure Therapeutics.
• [22] Clinical pipeline report, company report or official report of Vanda Pharmaceuticals.
• [23] Antiplasmodial drug targets: a patent review (2000 - 2013).Expert Opin Ther Pat. 2016;26(1):107-30.
• [24] Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
• [25] DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
• [26] Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
• [27] HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
• [28] US patent application no. 2009,0162,329, Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure.
• [29] ENTREMED TO ACQUIRE MIIKANA THERAPEUTICS. U.S. Securities and Exchange Commission. December 22, 2005.
• [30] Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
• [31] Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8.
• [32] New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7.
• [33] Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
• [34] Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
• [35] Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
• [36] Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
• [37] Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243.
• [38] Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81.
• [39] Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
• [40] Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
• [41] Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
• [42] Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84.
• [43] Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20.
• [44] Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
• [45] Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
• [46] Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6.
• [47] Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72.
• [48] Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J Med Chem. 1999 Nov 4;42(22):4669-79.
• [49] Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3023-6.
• [50] N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
• [51] Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 May 15;19(10):2840-3.
• [52] Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S20-6.
• [53] Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni. Mol Biochem Parasitol. 2009 Nov;168(1):7-15.